Eintrag weiter verarbeiten
Use of statins offsets insulin‐related cancer risk
Gespeichert in:
| Zeitschriftentitel: | Journal of Internal Medicine |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Journal of Internal Medicine, 281, 2017, 2, S. 206-216 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Kautzky‐Willer, A. Thurner, S. Klimek, P. Kautzky‐Willer, A. Thurner, S. Klimek, P. |
|---|---|
| author |
Kautzky‐Willer, A. Thurner, S. Klimek, P. |
| spellingShingle |
Kautzky‐Willer, A. Thurner, S. Klimek, P. Journal of Internal Medicine Use of statins offsets insulin‐related cancer risk Internal Medicine |
| author_sort |
kautzky‐willer, a. |
| spelling |
Kautzky‐Willer, A. Thurner, S. Klimek, P. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.12567 <jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>There is firm evidence of a relation between type 2 diabetes (T2DM) and increased risks of cancer at various sites, but it is still unclear how different antihyperglycaemic therapies modify site‐specific cancer risks. The aim of this study was to provide a complete characterization of all possible associations between individual T2DM therapies, statin use and site‐specific cancers in the Austrian population.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Medical claims data of 1 847 051 patients with hospital stays during 2006–2007 were used to estimate age‐ and sex‐dependent co‐occurrences of site‐specific cancer diagnoses and treatment with specific glucose‐lowering drugs and statins.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients treated with insulin or insulin secretagogues showed up to ninefold increased risks for cancers of the colon [males only (m)], liver (m), pancreas, lung (m) and brain (m), as well as a strongly decreased risk for prostate cancer (m). In patients taking statins, the risks were generally decreased, with a greater risk reduction in patients not receiving antihyperglycaemic therapies. The strongest effects were observed for use of insulin and pancreatic cancer [m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.5, 95% CI: 3.1–6.6; females (f): <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.2, 95% CI: 2.5–7.1], sulfonylureas (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 2.8, 95% CI: 1.7–4.6; f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 3.0, 95% CI: 2.1–4.2) or glitazones and skin cancer (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.54, 95% CI: 0.36–0.80), as well as metformin and cancer of the prostate (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.82, 95% CI: 0.75–0.91) and corpus uteri (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 1.7, 95% CI: 1.4–2.0) and non‐Hodgkin's lymphoma (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.76, 95% CI: 0.64–0.91).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The use of statins offsets insulin‐related cancer risks in patients with diabetes independently of sex and age. Overall, our data support the hyperglycaemia–cancer hypothesis. A reduction in endogenous or exogenous hyperinsulinaemia may be beneficial for cancer prevention. Therefore, insulin‐sparing and insulin‐sensitizing drugs should be the preferred treatment choices.</jats:p></jats:sec> Use of statins offsets insulin‐related cancer risk Journal of Internal Medicine |
| doi_str_mv |
10.1111/joim.12567 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjEyNTY3 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjEyNTY3 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2017 |
| imprint_str_mv |
Wiley, 2017 |
| issn |
0954-6820 1365-2796 |
| issn_str_mv |
0954-6820 1365-2796 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
kautzkywiller2017useofstatinsoffsetsinsulinrelatedcancerrisk |
| publishDateSort |
2017 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Internal Medicine |
| source_id |
49 |
| title |
Use of statins offsets insulin‐related cancer risk |
| title_unstemmed |
Use of statins offsets insulin‐related cancer risk |
| title_full |
Use of statins offsets insulin‐related cancer risk |
| title_fullStr |
Use of statins offsets insulin‐related cancer risk |
| title_full_unstemmed |
Use of statins offsets insulin‐related cancer risk |
| title_short |
Use of statins offsets insulin‐related cancer risk |
| title_sort |
use of statins offsets insulin‐related cancer risk |
| topic |
Internal Medicine |
| url |
http://dx.doi.org/10.1111/joim.12567 |
| publishDate |
2017 |
| physical |
206-216 |
| description |
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>There is firm evidence of a relation between type 2 diabetes (T2DM) and increased risks of cancer at various sites, but it is still unclear how different antihyperglycaemic therapies modify site‐specific cancer risks. The aim of this study was to provide a complete characterization of all possible associations between individual T2DM therapies, statin use and site‐specific cancers in the Austrian population.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Medical claims data of 1 847 051 patients with hospital stays during 2006–2007 were used to estimate age‐ and sex‐dependent co‐occurrences of site‐specific cancer diagnoses and treatment with specific glucose‐lowering drugs and statins.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients treated with insulin or insulin secretagogues showed up to ninefold increased risks for cancers of the colon [males only (m)], liver (m), pancreas, lung (m) and brain (m), as well as a strongly decreased risk for prostate cancer (m). In patients taking statins, the risks were generally decreased, with a greater risk reduction in patients not receiving antihyperglycaemic therapies. The strongest effects were observed for use of insulin and pancreatic cancer [m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.5, 95% CI: 3.1–6.6; females (f): <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.2, 95% CI: 2.5–7.1], sulfonylureas (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 2.8, 95% CI: 1.7–4.6; f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 3.0, 95% CI: 2.1–4.2) or glitazones and skin cancer (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.54, 95% CI: 0.36–0.80), as well as metformin and cancer of the prostate (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.82, 95% CI: 0.75–0.91) and corpus uteri (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 1.7, 95% CI: 1.4–2.0) and non‐Hodgkin's lymphoma (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.76, 95% CI: 0.64–0.91).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The use of statins offsets insulin‐related cancer risks in patients with diabetes independently of sex and age. Overall, our data support the hyperglycaemia–cancer hypothesis. A reduction in endogenous or exogenous hyperinsulinaemia may be beneficial for cancer prevention. Therefore, insulin‐sparing and insulin‐sensitizing drugs should be the preferred treatment choices.</jats:p></jats:sec> |
| container_issue |
2 |
| container_start_page |
206 |
| container_title |
Journal of Internal Medicine |
| container_volume |
281 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334328341987334 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:26:54.617Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Use+of+statins+offsets+insulin%E2%80%90related+cancer+risk&rft.date=2017-02-01&genre=article&issn=1365-2796&volume=281&issue=2&spage=206&epage=216&pages=206-216&jtitle=Journal+of+Internal+Medicine&atitle=Use+of+statins+offsets+insulin%E2%80%90related+cancer+risk&aulast=Klimek&aufirst=P.&rft_id=info%3Adoi%2F10.1111%2Fjoim.12567&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334328341987334 |
| author | Kautzky‐Willer, A., Thurner, S., Klimek, P. |
| author_facet | Kautzky‐Willer, A., Thurner, S., Klimek, P., Kautzky‐Willer, A., Thurner, S., Klimek, P. |
| author_sort | kautzky‐willer, a. |
| container_issue | 2 |
| container_start_page | 206 |
| container_title | Journal of Internal Medicine |
| container_volume | 281 |
| description | <jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>There is firm evidence of a relation between type 2 diabetes (T2DM) and increased risks of cancer at various sites, but it is still unclear how different antihyperglycaemic therapies modify site‐specific cancer risks. The aim of this study was to provide a complete characterization of all possible associations between individual T2DM therapies, statin use and site‐specific cancers in the Austrian population.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Medical claims data of 1 847 051 patients with hospital stays during 2006–2007 were used to estimate age‐ and sex‐dependent co‐occurrences of site‐specific cancer diagnoses and treatment with specific glucose‐lowering drugs and statins.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients treated with insulin or insulin secretagogues showed up to ninefold increased risks for cancers of the colon [males only (m)], liver (m), pancreas, lung (m) and brain (m), as well as a strongly decreased risk for prostate cancer (m). In patients taking statins, the risks were generally decreased, with a greater risk reduction in patients not receiving antihyperglycaemic therapies. The strongest effects were observed for use of insulin and pancreatic cancer [m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.5, 95% CI: 3.1–6.6; females (f): <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.2, 95% CI: 2.5–7.1], sulfonylureas (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 2.8, 95% CI: 1.7–4.6; f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 3.0, 95% CI: 2.1–4.2) or glitazones and skin cancer (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.54, 95% CI: 0.36–0.80), as well as metformin and cancer of the prostate (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.82, 95% CI: 0.75–0.91) and corpus uteri (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 1.7, 95% CI: 1.4–2.0) and non‐Hodgkin's lymphoma (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.76, 95% CI: 0.64–0.91).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The use of statins offsets insulin‐related cancer risks in patients with diabetes independently of sex and age. Overall, our data support the hyperglycaemia–cancer hypothesis. A reduction in endogenous or exogenous hyperinsulinaemia may be beneficial for cancer prevention. Therefore, insulin‐sparing and insulin‐sensitizing drugs should be the preferred treatment choices.</jats:p></jats:sec> |
| doi_str_mv | 10.1111/joim.12567 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qb2ltLjEyNTY3 |
| imprint | Wiley, 2017 |
| imprint_str_mv | Wiley, 2017 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0954-6820, 1365-2796 |
| issn_str_mv | 0954-6820, 1365-2796 |
| language | English |
| last_indexed | 2024-03-01T14:26:54.617Z |
| match_str | kautzkywiller2017useofstatinsoffsetsinsulinrelatedcancerrisk |
| mega_collection | Wiley (CrossRef) |
| physical | 206-216 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Journal of Internal Medicine |
| source_id | 49 |
| spelling | Kautzky‐Willer, A. Thurner, S. Klimek, P. 0954-6820 1365-2796 Wiley Internal Medicine http://dx.doi.org/10.1111/joim.12567 <jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>There is firm evidence of a relation between type 2 diabetes (T2DM) and increased risks of cancer at various sites, but it is still unclear how different antihyperglycaemic therapies modify site‐specific cancer risks. The aim of this study was to provide a complete characterization of all possible associations between individual T2DM therapies, statin use and site‐specific cancers in the Austrian population.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Medical claims data of 1 847 051 patients with hospital stays during 2006–2007 were used to estimate age‐ and sex‐dependent co‐occurrences of site‐specific cancer diagnoses and treatment with specific glucose‐lowering drugs and statins.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients treated with insulin or insulin secretagogues showed up to ninefold increased risks for cancers of the colon [males only (m)], liver (m), pancreas, lung (m) and brain (m), as well as a strongly decreased risk for prostate cancer (m). In patients taking statins, the risks were generally decreased, with a greater risk reduction in patients not receiving antihyperglycaemic therapies. The strongest effects were observed for use of insulin and pancreatic cancer [m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.5, 95% CI: 3.1–6.6; females (f): <jats:styled-content style="fixed-case">OR</jats:styled-content> 4.2, 95% CI: 2.5–7.1], sulfonylureas (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 2.8, 95% CI: 1.7–4.6; f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 3.0, 95% CI: 2.1–4.2) or glitazones and skin cancer (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.54, 95% CI: 0.36–0.80), as well as metformin and cancer of the prostate (m: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.82, 95% CI: 0.75–0.91) and corpus uteri (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 1.7, 95% CI: 1.4–2.0) and non‐Hodgkin's lymphoma (f: <jats:styled-content style="fixed-case">OR</jats:styled-content> 0.76, 95% CI: 0.64–0.91).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The use of statins offsets insulin‐related cancer risks in patients with diabetes independently of sex and age. Overall, our data support the hyperglycaemia–cancer hypothesis. A reduction in endogenous or exogenous hyperinsulinaemia may be beneficial for cancer prevention. Therefore, insulin‐sparing and insulin‐sensitizing drugs should be the preferred treatment choices.</jats:p></jats:sec> Use of statins offsets insulin‐related cancer risk Journal of Internal Medicine |
| spellingShingle | Kautzky‐Willer, A., Thurner, S., Klimek, P., Journal of Internal Medicine, Use of statins offsets insulin‐related cancer risk, Internal Medicine |
| title | Use of statins offsets insulin‐related cancer risk |
| title_full | Use of statins offsets insulin‐related cancer risk |
| title_fullStr | Use of statins offsets insulin‐related cancer risk |
| title_full_unstemmed | Use of statins offsets insulin‐related cancer risk |
| title_short | Use of statins offsets insulin‐related cancer risk |
| title_sort | use of statins offsets insulin‐related cancer risk |
| title_unstemmed | Use of statins offsets insulin‐related cancer risk |
| topic | Internal Medicine |
| url | http://dx.doi.org/10.1111/joim.12567 |